Clinical Significance

The mortality statistics of cardiac amyloidosis are alarming and underscore the urgency of early diagnosis and therapy. The 5-year mortality of cardiac amyloidosis is estimated at approximately 60% — placing it in a category alongside the most aggressive malignancies. In AL amyloidosis with cardiac involvement, the prognosis is particularly grim: mortality rates reach up to 50% per year after the first cardiac decompensation. Untreated AA amyloidosis shows a median survival of only 3–4 years. Compared to other cardiomyopathies (hypertrophic, dilated, ischemic), cardiac amyloidosis shows markedly worse prognosis.

Cardiac manifestation leads to characteristic restrictive cardiomyopathy presenting initially as diastolic dysfunction, progressively developing into combined systolic-diastolic heart failure. Untreated, this progression is relentless and leads to repeated hospitalizations, reduced quality of life, and ultimately death. The hemodynamic changes are complex and fundamentally different from other forms of heart failure. Amyloid deposits lead to progressive myocardial thickening without a corresponding improvement in contractile function — the characteristic phenomenon of 'pseudonormal' ejection fraction despite massive wall thickening makes echocardiographic diagnosis particularly challenging.

Renal involvement in amyloidosis — particularly AL — represents a further dimension of morbidity. Amyloid deposits can occur both in vascular structures and glomerular capillaries of the kidney. The vascular form (approx. 10% of cases) can lead to renal function loss without detectable proteinuria. The more common glomerular form manifests as nephrotic syndrome with massive proteinuria, hypoproteinemia, edema, and progressive renal insufficiency. When dialysis becomes necessary due to amyloidosis, median life expectancy in AL amyloidosis is only 26 months.

Neurological manifestations — particularly in hereditary ATTR — lead to progressive functional limitations dramatically affecting patients' quality of life and independence. The characteristic distally-beginning sensorimotor polyneuropathy develops insidiously but leads to increasing sensory disturbances, pain, and motor deficits. Autonomic neuropathy can have severe consequences including gastrointestinal motility disorders, orthostatic hypotension, and cardiovascular dysregulation — often underdiagnosed but contributing significantly to morbidity.

Gastrointestinal manifestations can lead to considerable morbidity. Macroglossia — a characteristic sign of AL amyloidosis — can cause dysphagia, airway obstruction, and speech disorders. GI motility disorders cause malabsorption, weight loss, and potentially dangerous electrolyte disturbances. Hepatic involvement typically leads to hepatomegaly with characteristic rock-hard consistency on palpation and marked elevation of alkaline phosphatase with only moderate transaminase elevation.

The socioeconomic impact of amyloidosis is substantial and affects both individual patients and the healthcare system. Diagnostic delay leads to repeated physician visits, unnecessary investigations, and inadequate treatments. Costs from treating complications — repeated heart failure hospitalizations, dialysis, neurological complication treatment — generate high direct costs. The indirect costs from work incapacity, early retirement, and care dependency are also considerable. Misdiagnosis costs the healthcare system billions through ineffective treatments and repeated hospitalizations.

The impact of amyloidosis on quality of life is dramatic and multidimensional. Progressive heart failure leads to increasing exercise intolerance, dyspnea, and fatigue — patients experience continuous deterioration of functional capacity measurable through 6-minute walk test. Neurological manifestations cause pain, sensory disturbances, and motor deficits that significantly impair daily activities. The combination of cardiac, renal, and neurological symptoms creates a complex symptom burden requiring comprehensive multidisciplinary care.

The clinical relevance of amyloidosis extends across multiple medical specialties:

This cross-specialty relevance makes multidisciplinary amyloidosis centers essential for timely diagnosis.